Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myocarditis I: Introduction01:21

Myocarditis I: Introduction

293
Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
293
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

129
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
129
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

255
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
255
Myocarditis IV: Nursing Management01:22

Myocarditis IV: Nursing Management

166
Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
166
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

383
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
383
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

430
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
430

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Atrial Fibrosis Imaging: Correlation of Late Gadolinium Enhancement Magnetic Resonance Imaging With High-Definition Voltage Electroanatomical Mapping Across Different Thresholds.

Journal of cardiovascular electrophysiology·2026
Same author

Coronary Flow Reserve in Adults: Pathophysiology, Assessment Modalities, Clinical Applications, and Prognostic Significance.

Medicina (Kaunas, Lithuania)·2026
Same author

Hypertension in autoimmune rheumatic diseases: a position paper from the European Society of Hypertension working group on small arteries. Part A: pathophysiology, prevalence and cardiovascular risk estimation.

Journal of hypertension·2026
Same author

Hypertension in autoimmune rheumatic diseases - a position paper from the European Society of Hypertension working group on small arteries. Part B: Recommendations for the clinical management of hypertension.

Journal of hypertension·2026
Same author

Myocardial deformation links combined liraglutide-empagliflozin therapy with improved cardiovascular and economic outcomes in type 2 diabetes: a 6-year study.

European heart journal. Imaging methods and practice·2026
Same author

Effects of dapagliflozin and dulaglutide on blood pressure and coronary flow in liver steatosis patients with type 2 diabetes.

Journal of hypertension·2026

Related Experiment Video

Updated: Dec 30, 2025

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy
07:40

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy

Published on: May 26, 2023

1.5K

Chronic inflammatory diseases, myocardial function and cardioprotection.

Antigone Lazou1, Ignatios Ikonomidis2, Monika Bartekova3

  • 1School of Biology, Aristotle University of Thessaloniki, Thessaloniki, Greece.

British Journal of Pharmacology
|January 17, 2020
PubMed
Summary

Chronic inflammatory diseases (CIDs) significantly increase cardiovascular risk. This review explores the mechanisms, cardiac effects, and treatments for CID-related cardiovascular disease (CVD), offering therapeutic recommendations.

More Related Videos

Myocardial Infarction and Functional Outcome Assessment in Pigs
12:03

Myocardial Infarction and Functional Outcome Assessment in Pigs

Published on: April 25, 2014

28.5K
Simultaneous 3D Analysis of Cardiac Damage and Immune Response in Reperfused Acute Myocardial Infarction Using Light Sheet Fluorescence Microscopy
06:38

Simultaneous 3D Analysis of Cardiac Damage and Immune Response in Reperfused Acute Myocardial Infarction Using Light Sheet Fluorescence Microscopy

Published on: September 26, 2025

948

Related Experiment Videos

Last Updated: Dec 30, 2025

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy
07:40

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy

Published on: May 26, 2023

1.5K
Myocardial Infarction and Functional Outcome Assessment in Pigs
12:03

Myocardial Infarction and Functional Outcome Assessment in Pigs

Published on: April 25, 2014

28.5K
Simultaneous 3D Analysis of Cardiac Damage and Immune Response in Reperfused Acute Myocardial Infarction Using Light Sheet Fluorescence Microscopy
06:38

Simultaneous 3D Analysis of Cardiac Damage and Immune Response in Reperfused Acute Myocardial Infarction Using Light Sheet Fluorescence Microscopy

Published on: September 26, 2025

948

Area of Science:

  • Cardiology
  • Rheumatology
  • Immunology

Background:

  • Chronic inflammatory diseases (CIDs) are linked to heightened cardiovascular (CV) risk, a serious complication.
  • The precise cellular and biochemical pathways driving this increased CV risk in CIDs are not fully understood.
  • Animal models for studying cardiac involvement in CIDs have limitations.

Purpose of the Study:

  • To review cardiac manifestations, risk factors, and pathogenetic mechanisms of cardiovascular disease (CVD) in five major CIDs.
  • To analyze the impact of CID treatments on myocardial function and explore cardioprotective strategies.
  • To propose recommendations for targeting shared pathways in CIDs and CVD for improved therapeutic design.

Main Methods:

  • Literature review focusing on cardiac manifestations in rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, psoriasis, and inflammatory bowel disease.
  • Analysis of pathogenetic mechanisms linking CIDs to cardiovascular complications.
  • Evaluation of treatment effects on cardiovascular outcomes and cardioprotection.

Main Results:

  • CIDs present with diverse cardiac manifestations and associated risk factors.
  • Pathogenetic mechanisms involve complex cellular and biochemical pathways.
  • Treatments for CIDs have variable effects on cardiac function, with some offering cardioprotection and others posing direct toxicity.

Conclusions:

  • Understanding the interplay between CIDs and CVD is crucial for patient management.
  • Targeting common pathways may lead to novel therapeutic strategies for CID-related CVD.
  • Further research is needed to elucidate mechanisms and optimize cardioprotective treatments in CID patients.